Market Overview

UPDATE: JP Morgan Upgrades C.R. Bard to Overweight on Litigation and Data Outlook

Share:
Related BCR
Earnings Scheduled For April 26, 2017
Benzinga's Top Upgrades, Downgrades For April 25, 2017
Mackenzie Financial Corp Buys C.R. Bard Inc, Automatic Data Processing Inc, Fortis Inc, Sells ... (GuruFocus)

JP Morgan raised its rating on C.R. Bard (NYSE: BCR) from Neutral to Overweight and increased its price target from $110 to $116.

JP Morgan noted, "We are upgrading shares of C.R. Bard from Neutral to Overweight in anticipation of (1) a favorable resolution of the Gore patent litigation; (2) significant upward revisions to Street estimates as models more accurately reflect the Gore awards and ongoing royalty stream; and (3) a positive outcome to the LEVANT 2 pivotal trial for Bard's Lutonix drug-coated balloon. Bard's base business continues to struggle; however, management has the potential with the Gore proceeds and royalty stream to create a pipeline in addition to Lutonix and with it a 2015 growth acceleration story, all while delivering solid double-digit EPS growth in the interim."

C.R. Bard closed at $95.99 on Monday.

Latest Ratings for BCR

DateFirmActionFromTo
Apr 2017BMO CapitalDowngradesOutperformMarket Perform
Apr 2017Wells FargoDowngradesOutperformMarket Perform
Apr 2017Raymond JamesDowngradesStrong BuyMarket Perform

View More Analyst Ratings for BCR
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (BCR)

View Comments and Join the Discussion!